Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Atorvastatin + Ezetimibe

Fixed-dose combination: statin plus intestinal cholesterol absorption inhibitor

ATC code: C10BA05(Atorvastatin and ezetimibe)

Updated · Methodology

Indications

A

Dyslipidemia

Second line

Primary hypercholesterolemia and mixed dyslipidemia in patients not reaching -C goal on the maximum tolerated dose of atorvastatin. Per 2019 and SEA 2023, post-MI or post-stroke LDL-C goal is <55 mg/dL; very high ASCVD risk also <55 mg/dL; high risk <70 mg/dL. Dose: 10/10, 20/10, 40/10, 80/10 mg once daily in the evening (cholesterol synthesis peaks at night). Effect at 4–6 weeks; lipid check at 6–8 weeks and every 6–12 months thereafter.

Sources

  1. AEMPS: Ficha técnica de Atorvastatina + Ezetimiba (2024)
  2. ESC/EAS: 2019 ESC/EAS Guidelines for the management of dyslipidaemias (2019)

ICD-10: E78 · ICD-11: 5C80

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

D

Anti-aging and longevity

Not recommended

Atorvastatin + ezetimibe is sometimes sold as a longevity drug and as cholesterol lowering for healthy young adults with -C <130 mg/dL and ASCVD risk <5%. Per 2019, 2018, and SEA 2023, statin therapy is not initiated for ASCVD risk <5% – benefits do not exceed harms (myopathy, transaminitis, hyperglycemia). Ezetimibe + statin has no indication in young patients without diagnosed dyslipidemia or familial hypercholesterolemia. If prescribed for anti-aging without calculation or a familial form, consider getting a second opinion and a formal ASCVD risk estimate.

Sources

  1. AEMPS: Ficha técnica de Atorvastatina + Ezetimiba (2024)
  2. Cochrane: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (2012)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Atorvastatin blocks HMG-CoA reductase in the liver – hepatocytes synthesize less cholesterol and take up more from the bloodstream. Ezetimibe blocks the intestinal NPC1L1 protein, reducing dietary and biliary cholesterol absorption. Additive effect: on top of the 30–50% LDL-C reduction from the statin, ezetimibe adds another 20–25%. IMPROVE-IT (NEJM 2015) showed a 6.4% reduction in cardiovascular events over 7 years.

Safety

Contraindications

  • Hypersensitivity
  • Active liver disease or persistent unexplained transaminase elevation
  • Pregnancy and breastfeeding
  • Concomitant strong CYP3A4 inhibitors at high doses (telaprevir, tipranavir/ritonavir)

Serious adverse effects

  • Rhabdomyolysis (rare)
  • Acute liver injury
  • Immune-mediated necrotizing myopathy (anti-HMGCR antibodies)
  • Hemorrhagic stroke in prior-stroke patients (SPARCL – rare)

Common adverse effects

  • Myalgia
  • Arthralgia
  • GI upset
  • Transaminase elevation
  • Headache
  • Slightly higher risk of new-onset type 2 diabetes in predisposed

Pregnancy: can you take Atorvastatin + Ezetimibe?

Contraindicated. Statins are teratogenic (impair fetal cholesterol synthesis). Effective contraception in women of reproductive age; stop the statin 1–2 months before planned conception.

Breastfeeding: can you take Atorvastatin + Ezetimibe?

Contraindicated. Statins pass into milk in clinically relevant amounts; theoretical risk for infant neurodevelopment. Defer statin therapy during breastfeeding or use only colestyramine/colestipol (non-absorbed).

Calculate RIDFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Monitoring

ALT/AST at baseline and on hepatitis symptoms; not routinely. CK only on muscle pain or weakness. -C and every 6–12 months (statins slightly raise blood glucose).

Drug interactions

Atorvastatin is a CYP3A4 substrate. Grapefruit juice, clarithromycin, itraconazole, and cyclosporine raise levels and myopathy risk. Hold the statin during macrolide or azole courses.

Drug–nutrient interactions

Grapefruit juice

The atorvastatin in this combination is broken down by CYP3A4, and grapefruit juice slows that enzyme. In the Atozet SmPC, one 240 ml glass a day raised atorvastatin exposure by 37%, and more than 1.2 litres a day for 5 days raised it 2.5-fold. The SmPC advises against large amounts of grapefruit juice with this medicine. Unexplained muscle pain or weakness, or dark urine, calls for a creatine kinase test.

Source: AEMPS: Ficha técnica de Atozet 10 mg/20 mg comprimidos recubiertos con película (ezetimiba y atorvastatina) (2023)

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Atorvastatin + Ezetimibe used for?

Atorvastatin + Ezetimibe is evaluated for the following indications with varying evidence strength: Dyslipidemia (evidence tier A), Anti-aging and longevity (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Atorvastatin + Ezetimibe?

Common side effects of Atorvastatin + Ezetimibe (≥ 1 in 100): Myalgia, Arthralgia, GI upset, Transaminase elevation, Headache, Slightly higher risk of new-onset type 2 diabetes in predisposed. See the Safety section for uncommon and serious reactions.

Is Atorvastatin + Ezetimibe safe during pregnancy?

Contraindicated. Statins are teratogenic (impair fetal cholesterol synthesis). Effective contraception in women of reproductive age; stop the statin 1–2 months before planned conception.

Is Atorvastatin + Ezetimibe compatible with breastfeeding?

Contraindicated. Statins pass into milk in clinically relevant amounts; theoretical risk for infant neurodevelopment. Defer statin therapy during breastfeeding or use only colestyramine/colestipol (non-absorbed).

Who should not take Atorvastatin + Ezetimibe?

Atorvastatin + Ezetimibe is contraindicated in: Hypersensitivity; Active liver disease or persistent unexplained transaminase elevation; Pregnancy and breastfeeding; Concomitant strong CYP3A4 inhibitors at high doses (telaprevir, tipranavir/ritonavir). Full list in the Safety section.

Other drugs in this group

Cod liver oil, Ezetimibe, Fluvastatin, Gemfibrozil, Lovastatin, Pravastatin, Simvastatin, Krill oil